Aceclofenac

Base Information

• Chemical Name: Aceclofenac
• CAS No.: 89796-99-6
• Molecular Formula: C16H13Cl2NO4
• Molecular Weight: 354.19
• Hs Code.: 29224999
• European Community (EC) Number: 641-844-5
• UNII: RPK779R03H
• DSSTox Substance ID: DTXSID7045522
• Nikkaji Number: J22.763C
• Wikipedia: Aceclofenac
• Wikidata: Q481757
• NCI Thesaurus Code: C80534
• Pharos Ligand ID: 5MR3LCHHL39J
• Metabolomics Workbench ID: 149943
• ChEMBL ID: CHEMBL93645
• Mol file: 89796-99-6.mol

Synonyms:2-((2,6-dichlorophenyl)amino)phenylacetoxyacetic acid;aceclofenac;Airtal;Airtal Difucrem;Aital;Beofenac;Biofenac;Bristaflam;Clanza CR;Falcol;Falcol Difucrem;Gerbin;Gerbin Difucrem;Preservex;Sanein

Chemical Property of Aceclofenac

Chemical Property:

• Appearance/Colour: White crystalline solid
• Vapor Pressure: 2.93E-10mmHg at 25°C
• Melting Point: 149-153 °C
• Refractive Index: 1.639
• Boiling Point: 486 °C at 760 mmHg
• PKA: 2.60±0.10(Predicted)
• Flash Point: 247.7 °C
• PSA: 75.63000
• Density: 1.455 g/cm³
• LogP: 3.98030
• Storage Temp.: -20°C Freezer
• Solubility.: Soluble in DMSO
• Water Solubility.: 32mg/L(32 oC)
• XLogP3: 4.3
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 7
• Exact Mass: 353.0221633
• Heavy Atom Count: 23
• Complexity: 411

Purity/Quality:

99.5% ^*data from raw suppliers

Aceclofenac-d4 ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T,N
• Hazard Codes: T,N
• Statements: 25-36-50/53
• Safety Statements: 26-45-60-61

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl
• Recent ClinicalTrials: Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole
• Description: Aceclofenac is a non-steroidal anti-inflammatory drug (NSAIDs) that is commonly prescribed for people with painful rheumatic conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. The drug should not be given to children, breastfeeding mothers, and people with porphyria. Pregnant women should not also be given aceclofenac as they risk developing patent ductus arteriosus in the neonate. Aceclofenac is a nonsteroidal antiinflammatory agent with analgesic and antipyretic properties. It is reported to be useful in the treatment of osteoarthritis, rheumatoid arthritis and pain associated with minor surgical procedures. Compared to ketoprofen in the treatment of rheumatoid arthritis, aceclofenac is substantially faster acting.
• Uses: Labeled Aceclofenac, intended for use as an internal standard for the quantification of Aceclofenac by GC- or LC-mass spectrometry. Aceclofenac is a non-steroidal, anti-inflammatory drug (NSAID) with potent inhibitory activity in several models of inflammation. It is used for the treatment of osteoarthritis and rheumatoid arthritis. It is a Biopharmaceutics classification system class II (BCS class I) drug which has an intermediate half-life of 3-4h and undergoes substantial first pass metabolism. aceclofenac is available either in oral form (tablet) or in topical form (gel).
• Drug interactions: Potentially hazardous interactions with other drugs ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia. Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage). Antibacterials: possible increased risk of convulsions with quinolones. Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban - avoid long term use with edoxaban. Antidepressants: increased risk of bleeding with SSRIs and venlaflaxine. Antidiabetic agents: effects of sulphonylureas enhanced. Antiepileptics: possibly increased phenytoin concentration. Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir. Ciclosporin: may potentiate nephrotoxicity Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib. Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect, hyperkalaemia with potassium-sparing diuretics. Lithium: excretion decreased. Pentoxifylline: increased risk of bleeding. Tacrolimus: increased risk of nephrotoxicity.

Technology Process of Aceclofenac

There total 6 articles about Aceclofenac which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 98.5%

2-((2,6-dichlorophenyl)amino)phenylacetoxyacetic acid tert-butyl ester (139272-68-7) → aceclofenac (89796-99-6)

Guidance literature:

With hydrogenchloride; acetic anhydride; acetic acid; In water; at 60 ℃; for 3h; Temperature;

Reference yield: 95.0%

tert-butyl-[2-(2,6-dichloroanilino) phenyl] acetoxy acetate → aceclofenac (89796-99-6)

Guidance literature:

With formic acid; In toluene; at 0 - 35 ℃; for 2h; Product distribution / selectivity;

Reference yield:

C35H29Cl2NO10 → aceclofenac (89796-99-6)

Guidance literature:

With simulated intestinalfluid; In methanol; at 37 ℃; pH=7.4; Reagent/catalyst; pH-value; Solvent;

DOI:10.1007/s00044-015-1469-7

upstream raw materials:

aceclofenac benzyl ester

diclofenac sodium

2-((2,6-dichlorophenyl)amino)phenylacetoxyacetic acid tert-butyl ester

Downstream raw materials:

1-(2,6-dichlorophenyl)indolin-2-one

[2-(2,6-dichloroanilino)phenyl]acetic acid

Refernces

• 1、 -. "METHODS FOR PREPARING ACECLOFENAC AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME". Paragraph 0111; 0113; 0115. . Retrieved 2020/10/20.
• 2、 -. "Aceclofenac preparation method". Paragraph 0029-0031; 0032-0034; 0035-0037; 0038-0069. . Retrieved 2018/09/08.